The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder
- PMID: 33769860
- PMCID: PMC10390940
- DOI: 10.18553/jmcp.2021.27.4.528
The effectiveness and value of digital health technologies as an adjunct to medication-assisted therapy for opioid use disorder
Abstract
DISCLOSURES: Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER's annual policy summit is supported by dues from AbbVie, Aetna, America's Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare. Whittington, Campbell, and Pearson are employed by ICER. Tice reports contracts to his institution, University of California, San Francisco, from ICER during the conduct of this study.
Conflict of interest statement
Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the Institute for Clinical and Economic Review (ICER), an independent organization that evaluates the evidence on the value of health care interventions. ICER’s annual policy summit is supported by dues from AbbVie, Aetna, America’s Health Insurance Plans, Anthem, Alnylam, AstraZeneca, Biogen, Blue Shield of CA, Boehringer-Ingelheim, Cambia Health Services, CVS, Editas, Evolve Pharmacy, Express Scripts, Genentech/Roche, GlaxoSmithKline, Harvard Pilgrim, Health Care Service Corporation, HealthFirst, Health Partners, Humana, Johnson & Johnson (Janssen), Kaiser Permanente, LEO Pharma, Mallinckrodt, Merck, Novartis, National Pharmaceutical Council, Pfizer, Premera, Prime Therapeutics, Regeneron, Sanofi, Spark Therapeutics, uniQure, and United Healthcare.
Whittington, Campbell, and Pearson are employed by ICER. Tice reports contracts to his institution, University of California, San Francisco, from ICER during the conduct of this study.
Similar articles
-
The effectiveness and value of belimumab and voclosporin for lupus nephritis.J Manag Care Spec Pharm. 2021 Oct;27(10):1495-1499. doi: 10.18553/jmcp.2021.27.10.1495. J Manag Care Spec Pharm. 2021. PMID: 34595943 Free PMC article.
-
Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis.J Manag Care Spec Pharm. 2021 Aug;27(8):1046-1055. doi: 10.18553/jmcp.2021.27.8.1046. J Manag Care Spec Pharm. 2021. PMID: 34337994 Free PMC article.
-
The effectiveness and value of eculizumab and efgartigimod for generalized myasthenia gravis.J Manag Care Spec Pharm. 2022 Jan;28(1):119-124. doi: 10.18553/jmcp.2022.28.1.119. J Manag Care Spec Pharm. 2022. PMID: 34949112 Free PMC article.
-
The effectiveness and value of targeted immune modulators for moderate to severe ulcerative colitis.J Manag Care Spec Pharm. 2021 Mar;27(3):405-410. doi: 10.18553/jmcp.2021.27.3.405. J Manag Care Spec Pharm. 2021. PMID: 33645245 Free PMC article.
-
The Effectiveness and Value of Rivaroxaban and Icosapent Ethyl as Additive Therapies for Cardiovascular Disease.J Manag Care Spec Pharm. 2020 Jun;26(6):782-785. doi: 10.18553/jmcp.2020.26.6.782. J Manag Care Spec Pharm. 2020. PMID: 32463783 Free PMC article. Review.
Cited by
-
Acceptability of VloV, a Mobile App Developed in Latin America for People with Substance Use Disorder among an Intensive Outpatient Treatment.Actas Esp Psiquiatr. 2025 Mar;53(2):304-314. doi: 10.62641/aep.v53i2.1701. Actas Esp Psiquiatr. 2025. PMID: 40071374 Free PMC article.
-
Recovery From Heroin Addiction: A Qualitative Study.Public Health Nurs. 2025 Mar-Apr;42(2):744-753. doi: 10.1111/phn.13526. Epub 2024 Dec 30. Public Health Nurs. 2025. PMID: 39740126 Free PMC article. Review.
-
The Composite Digital Therapeutic Index (cDTI): A Multidimensional Framework and Proof-of-Concept Application to FDA-Authorized Treatments.Cureus. 2025 May 11;17(5):e83886. doi: 10.7759/cureus.83886. eCollection 2025 May. Cureus. 2025. PMID: 40351480 Free PMC article.
-
Digital interventions targeting excessive substance use and substance use disorders: a comprehensive and systematic scoping review and bibliometric analysis.Front Psychiatry. 2024 Feb 5;15:1233888. doi: 10.3389/fpsyt.2024.1233888. eCollection 2024. Front Psychiatry. 2024. PMID: 38374977 Free PMC article.
References
-
- Kolodny A, Courtwright DT, Hwang CS, et al. . The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health. 2015;36:559-74. - PubMed
-
- Centers for Disease Control and Prevention. Provisional drug overdose death counts. 2018. Accessed March 4, 2021. https://www.cdc.goy/nchs/nvss/vsrr/drug-overdose-data.htm
-
- U.S. Department of Health and Human Services. National opioid crisis. 2019. Accessed March 4, 2021. http://www.hhs.gov/opioids
-
- Centers for Disease Control and Prevention. Overdose deaths accelerating during COVID-19. Updated December 18, 2020. Accessed March 4, 2021. https://www.cdc.gov/media/releases/2020/p1218-overdose-deaths-covid-19.html
-
- Council of Economic Advisors. The full cost of the opioid crisis: $2.5 trillion over four years. October 28, 2019. Accessed March 4, 2021. https://trumpwhitehouse.archives.gov/articles/full-cost-opioid-crisis-2-...